Xiao Lu-Xi, Li Xun-Jun, Yu Hai-Yi, Qiu Ren-Jie, Zhai Zhong-Ya, Ding Wen-Fu, Zhu Man-Sheng, Zhong Wu, Fang Chuan-Fa, Yang Jia, Chen Tao, Yu Jiang
Department of General Surgery, Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong Province, China.
Department of Gastrointestinal and Hernia Surgery, Ganzhou Hospital-Nanfang Hospital, Ganzhou 341099, Jiangxi Province, China.
World J Gastroenterol. 2024 Dec 21;30(47):5032-5054. doi: 10.3748/wjg.v30.i47.5032.
Advanced gastric tumors are extremely prone to metastasize the in 20%-30% of gastric cancer, and patients have a poor prognosis despite systemic chemotherapy. Peritoneal metastases from gastric cancer usually indicate the end stage of the disease without curative treatment.
To peritoneal metastasis for facilitating clinical therapy are urgently needed.
Immunohistochemical staining and immunofluorescence staining were used to demonstrate the high expression of cathepsin L (CTSL) in human gastric cancer tissues and its localization in cells. Lentivirus transfection was used to construct stable cell lines. Transwell invasion assays, wound healing assays, and animal tests were used to determine the relationships between CTSL and epithelial-mesenchymal transition (EMT) and tumorigenic potential .
We observed that macrophage-derived CTSL promoted gastric cancer cell migration and metastasis the EMT pathway and , which involved macrophage polarization. Our findings suggest that macrophages improve extracellular matrix remodeling and hence facilitate tumor metastasis. Ablation of CTSL in macrophages within the tumor microenvironment may improve tumor therapy and the prognosis of patients with gastric cancer peritoneal metastasis.
In consideration of our findings, tumor-associated macrophage-derived CTSL is an important factor that promotes the metastasis and invasion of gastric cancer cells, and the targeting of CTSL may potentially improve the prognosis of patients with gastric cancer with peritoneal metastasis.
进展期胃肿瘤极易发生转移,在20%-30%的胃癌中存在转移情况,尽管进行了全身化疗,患者的预后仍然很差。胃癌的腹膜转移通常预示着疾病的终末期,无法进行根治性治疗。
迫切需要用于促进临床治疗的腹膜转移相关研究。
采用免疫组织化学染色和免疫荧光染色来证实组织蛋白酶L(CTSL)在人胃癌组织中的高表达及其在细胞中的定位。利用慢病毒转染构建稳定细胞系。采用Transwell侵袭实验、伤口愈合实验和动物实验来确定CTSL与上皮-间质转化(EMT)及致瘤潜能之间的关系。
我们观察到巨噬细胞衍生的CTSL通过EMT途径促进胃癌细胞迁移和转移,这涉及巨噬细胞极化。我们的研究结果表明,巨噬细胞可改善细胞外基质重塑,从而促进肿瘤转移。消除肿瘤微环境中巨噬细胞内的CTSL可能会改善肿瘤治疗效果以及胃癌腹膜转移患者的预后。
鉴于我们的研究结果,肿瘤相关巨噬细胞衍生的CTSL是促进胃癌细胞转移和侵袭的重要因素,靶向CTSL可能会改善胃癌腹膜转移患者的预后。